While the company issued the recall April 5, the company failed to make the recall public per the FDA’s request. As a result, the federal agency issued a warning to healthcare professionals to dispose of the products.
The recall was initiated after visible particles were found in some of the drug vials intended for injection.
“Injection of a drug product containing particulate matter may result in serious and potentially life threatening adverse events, such as infection, allergic reaction, toxicity, or other reactions,” the FDA’s recall warning reads. “Healthcare professionals should immediately check their medical supplies, quarantine any sterile drug products intended for injection from Coastal Meds, and not administer them to patients.”
To date, no adverse events have been reported to the FDA as a result of the particulate matter discovered in these sterile products.
More articles on supply chain:
Amazon drops plan to become a major pharmaceutical distributor: 7 things to know
GSK divests line of rare disease drugs
FDA OKs 1st AI medical device that screens patients without physician interpretation
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.